DEVICE AND METHOD FOR DETERMINING ANALYTE LEVELS

• US 20130310666A1
• Filed: 07/23/2013
• Published: 11/21/2013
• Est. Priority Date: 03/04/1997
• Status: Active Grant

• Current Assignee: DexCom Incorporated
• Original Assignee: DexCom Incorporated
• Inventors: Shults, Mark C., Updike, Stuart J., Gilligan, Barbara J., Tapsak, Mark A., Rhodes, Rathbun K
• Granted Patent: US 8,923,947 B2
• Time in Patent Office: Days
• US Class Current: 600/316
• CPC Class Codes: A61B 2562/17 Comprising radiolucent components
• CPC Class Codes: A61B 5/0031 Implanted circuitry
• CPC Class Codes: A61B 5/14532 for measuring glucose, e.g. by tissue impedance measurement
• CPC Class Codes: A61B 5/1455 using optical sensors, e.g. spectral photometrical oximeters
• CPC Class Codes: A61B 5/14558 by polarisation
• CPC Class Codes: A61B 5/1459 invasive, e.g. introduced into the body by a catheter A61B5/1464 takes precedence
• CPC Class Codes: A61B 5/1486 using enzyme electrodes, e.g. with immobilised oxidase
• CPC Class Codes: A61B 5/14865 invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors
• CPC Class Codes: C12Q 1/006 for glucose

Abstract

Devices and methods for determining analyte levels are described. The devices and methods allow for the implantation of analyte-monitoring devices, such as glucose monitoring devices that result in the delivery of a dependable flow of blood to deliver sample to the implanted device. The devices include unique architectural arrangement in the sensor region that allows accurate data to be obtained over long periods of time.

Claims

1. An implantable optical-based continuous glucose sensing device, the device comprising:

a membrane comprising partial metallization of a distal side of the membrane, wherein the membrane is configured to interface with tissue;

a radiation source;

an optical sensor configured to measure a signal indicative of glucose concentration;

a housing configured to receive the radiation source and the optical sensor.

2. The device of claim 1, wherein the metallization comprises platinum.

3. The device of claim 1, wherein the metallization comprises vacuum deposited metal.

4. The device of claim 1, further comprising fluorescence sensing molecules configured to detect a presence of glucose.

5. The device of claim 1, wherein the membrane is configured to protect the sensor from in vivo environmental conditions.